Mymetics Corp (MYMX)

[bow-tie]

Pandemic moves and countermoves: vaccines and viral variants
Rogier W Sanders
Menno D de Jong
Published: March 30, 2021

In summary, the early findings reported by Emary and colleagues suggest a meaningful degree of efficacy against the B.1.1.7 variant, which is encouraging. However, additional data are clearly needed to fully appreciate the potential impact of this and other variants of concern on current and future vaccine efficacy, and to provide conclusive evidence that will inform important policy projections and decisions. The COV002 study is ongoing and we eagerly await further data during this anxious time.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00730-3/fulltext

COV002 STUDY (University of Oxford)
https://clinicaltrials.gov/ct2/show/NCT04400838